12/19/2025
📣 The Aifred Health team is very excited to close out a great 2025 by welcoming Louisa Petropoulos as its new CEO!
During the past 12 months, Aifred has seen tremendous success in achieving major milestones, including:
🌟 Publication of the results of our North American approval trial.
🌟 Publication of the validation study for our AI model in treatment response prediction.
🌟 Achieving our second US patent.
🌟 Successful completion of regulatory paths in both the US and Canada.
With these milestones under its belt, Aifred is ready and eager for the next phase of its journey! We are delighted to now welcome Louisa Petropoulos in the role of CEO, ready to take Aifred forward to even greater success in this new chapter.
Louisa brings a wealth of expertise to the Aifred team with experience across venture capital, biotech, clinical operations, and business development in Canada and the US. Most recently, she served as President & CEO of the cell therapy CDMO C3i Center Inc whereby under her leadership, C3i was transitioned from an academic institution to an internationally competitive CDMO becoming the first and only CDMO in Canada to obtain Drug Establishment License (DEL) for the commercial manufacturing of cell therapies as well as EMA approval for manufacturing for the EU and attracting international biotech clients.
Louisa’s strong scientific background is ideally matched to the extensive scientific foundations to our work that position Aifred as a responsible, safe and effective decision support tool for clinicians and patients alike.
Please join us in giving Louisa a very warm welcome indeed to the Aifred team!
